Germany Mammography Market Size

Germany Mammography Market Analysis

The Germany Mammography Market size is estimated at USD 126.65 million in 2024, and is expected to reach USD 193.62 million by 2029, growing at a CAGR of 8.86% during the forecast period (2024-2029).

The COVID pandemic had an adverse effect on market growth. Germany stopped all elective studies and treatments aimed at patients with advanced tumors as a result of COVID-19. In addition, a research letter from 2021 titled "Documented New Cases of Cancer in the Clinical Cancer Registries of the German State of Saxony during the COVID-19 Pandemic" noted that an evaluation of the anticipated and actual reports of new cancer cases revealed a notable decline during the lockdown period that began in March 2020. According to the study, there were almost 9% fewer incidences of breast cancer reported. Fewer doctor visits, a decline in statutory health insurance-funded services, fewer diagnostic referrals as examinations were delayed, and a reduction in the scope of skin cancer, colonoscopy, and mammography screenings provided after the nationwide lockdown were some of the causes of this decline in the documentation. Although there was a backlog of roughly a year's worth of mammography procedures, breast cancer screening techniques resumed to a greater extent in 2021, with clinics, diagnostic centers, and mobile units operating across the nation. The country experienced a number of difficulties with breast screening as a result of the aforementioned issues, but it is anticipated that the market will rebound.

Factors such as the technological advancements in breast imaging, and the investment from various organizations in breast cancer screening campaigns are driving the market. In Germany, the incidence of breast cancer is rising significantly. In Germany, the five-year prevalence of breast cancer was 299,702 in 2020, according to data from the International Agency for Research on Cancer. As a result, the nation's high breast cancer prevalence is anticipated to raise the demand for mammography, prompting individuals to visit clinics for screening. The market is anticipated to grow as a result. Initiatives by key market players are another factor in market growth. In January 2021, SOMATEX Medical Technology GmbH, a pioneer in biopsy site markers and localization technologies, was purchased by Hologic Inc. E-Med Solutions GmbH, Berlin, a consortium of investors led by the German private equity firm Westlake Partners, previously owned the business. Similarly, in January 2021, GE Healthcare ordered mobile mammography equipment from Toutenkamion Group for one of its clients, a private radiology clinic in Germany. Thus, the abovementioned factors are expected to increase the market growth.

However, the risk of adverse effects from radiation exposure, and reduction in reimbursement are expected to hinder the market growth.